TScan appoints Dr. Debora Barton as Chief Medical Officer effective July 5, 2022

TScan Therapeutics, Inc.

Appointed Dr. Debora Barton as CMO, effective July 5, 2022.
Barton previously CMO at Carisma Therapeutics and SVP at Iovance Biotherapeutics.
Employment terms: $450k base salary, option for 150k shares under 2021 equity plan.
Option vests 25% after 12 months, remainder in 36 monthly installments; eligible for 40% bonus target.
No family relationships or material transactions with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Debora Barton

Chief Medical Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2022-07-05
Filed: July 7, 2022, 7:59 PM ET

On July 7, 2022, TScan Therapeutics, Inc. (the “Company”), announced the appointment of Dr. Debora Barton, M.D., to serve as the Company’s Chief Medical Officer, effective July 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Debora Barton was appointed as Chief Medical Officer at TScan Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On July 7, 2022, TScan Therapeutics, Inc. (the “Company”), announced the appointment of Dr. Debora Barton, M.D., to serve as the Company’s Chief Medical Officer, effective July 5, 2022.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-189000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.